Posted in M&A / Deals Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout April 20, 2026 BioPharma Dive Worth up to $7 billion, Lilly s second recent acquisition of a company in the space is centered around a cell therapy that s currently in early-stage testing for multiple myeloma. M&A / DealsGene Therapy PlatformRead full story